Adequan, the “Official Joint Therapy Treatment,” Continues Partnership with USEA
The United States Eventing Association (USEA) is proud to announce that American Regent Animal Health, makers of Adequan i.m.® (polysulfated glycosaminoglycan), will remain a Corporate Sponsor for the 2025 and 2026 seasons. As the “Official Joint Therapy Treatment of the USEA,” Adequan will also continue its role as the title sponsor of the $60,000 Adequan USEA Advanced Final at the USEA American Eventing Championships (AEC).
The $60,000 Adequan USEA Advanced Final is the premier championship division held at the AEC, showcasing the top national level of the sport in the United States. This division features the nation’s elite horse-and-rider combinations competing at the Advanced level, the highest recognized level of national eventing competition. The 2025 Adequan Advanced Final will take place Aug. 26–31 at Galway Downs in Temecula, California. In 2026, the Adequan USEA Advanced Final will return to the Kentucky Horse Park in Lexington, Kentucky, for a three-year rotation.
Adequan i.m. is an FDA-approved joint therapy for the treatment of equine arthritis, also known as degenerative joint disease (DJD). For USEA members, Adequan offers a trusted solution that can help maintain the performance and well-being of their equine partners. It can offer benefits for all horses with DJD from the Starter level all the way through the highest levels of the sport. With this renewed sponsorship, Adequan i.m. strengthens its ongoing mission to support joint health of equine athletes and the future of American eventing. See below for indications and important safety information for Adequan i.m.
“For over 30 years, Adequan® has been a strong supporter of horses and riders, and we are thrilled to continue that tradition with the USEA,” said Marjorie Lathrop, marketing director at American Regent Animal Health. “We’re looking forward to another exciting competition season in the sport of eventing.”
“Adequan has been a dedicated partner of the USEA and the eventing community, and we are thrilled to continue this relationship,” said USEA CEO Rob Burk. “Their ongoing support of the sport, especially at the pinnacle of our national competition at the Advanced Final, is instrumental in providing opportunities for our top riders and horses. We deeply value their commitment to the health and longevity of our equine athletes.”
For more information, visit http://www.adequan.com.
Adequan® i.m. polysulfated glycosaminoglycan (PSGAG) solution 100 mg/mL
INDICATIONS
Adequan® i.m. is recommended for the intramuscular treatment of non-infectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses.
IMPORTANT SAFETY INFORMATION
There are no known contraindications to the use of intramuscular Polysulfated Glycosaminoglycan (PSGAG). Studies have not been conducted to establish safety in breeding horses. WARNING: Do not use in horses intended for human consumption. Not for use in humans. Keep this and all medications out of the reach of children. CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian. For additional safety information, please see full prescribing information at adequan.com.
About the United States Eventing Association
The USEA is a non-profit 501(c)(3) educational organization committed to providing eventing enthusiasts with a competitive level suited to their individual skills. By assisting and educating competitors, event organizers, and officials; maintaining responsible safety standards; and registering qualified competitions and clinics, the USEA offers a strong and continuous training opportunity for an ever-expanding field of world-class competitors. Just as importantly, the USEA provides a means for all riders, regardless of age or ability, to experience the thrill of eventing. To learn more, visit www.useventing.com.
About American Regent Animal Health
American Regent Animal Health, a division of American Regent, Inc., is committed to advancing animal health with proven FDA-approved products like Adequan® (polysulfated glycosaminoglycan). The company’s portfolio is anchored by the only FDA-approved polysulfated glycosaminoglycan products for horses and dogs, which have been relied on for over three decades by veterinarians. American Regent, Inc., a Daiichi Sankyo Group Company, manufactures and distributes human and veterinary pharmaceutical products and is committed to providing the ever-changing U.S. healthcare marketplace with a growing and diversified American Regent portfolio. For more information on American Regent Animal Health, visit ARAnimalHealth.com or call 800-458-0163.
PP-AI-US-1271
Related Articles
Big Improvements Arrive in ShowConnect for May & June 2025
ShowConnect has continued to evolve this summer, with a round of exciting updates designed to help event organizers manage entries more efficiently, communicate more clearly with riders and spectators, and reduce the friction in every phase of an event. These May and June improvements reflect wha...
Alec Lochore Appointed as Eventing Cross-Country Course Designer for 2028 Los Angeles Olympic Games
Alec Lochore (GBR), FEI Level 4 Course Designer and Technical Delegate, has been appointed as the eventing course designer for the Olympic Games in Los Angeles in 2028.
Give Back to the Sport at the 2025 USEA American Eventing Championships at Galway Downs
The USEA American Eventing Championships presented by Nutrena Feeds is a celebration of eventing at all levels of the sport that brings competitors together from across the country. This extraordinary feat isn’t achieved without the help of hundreds of volunteers that work tirelessly behind the s...
